Literature DB >> 25658545

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination.

M-R Lee1, C-Y Yang2, C-C Shu3, C-K Lin1, Y-F Wen1, S-W Lee4, J-C Ko1, J-Y Wang5, L-N Lee6, C-J Yu2.   

Abstract

Very few studies have focused on the outcome and management of patients with a single sputum isolate of nontuberculous mycobacterium (NTM) on initial examination. Patients with a single isolate of Mycobacterium avium complex (MAC), M. chelonae-abscessus, M. kansasii, or M. fortuitum from at least three sputum samples collected within 1 month were retrospectively identified. Those with follow-up sputum samples within 1 year were included in the analysis. Among the 202 patients included, M. fortuitum (n = 71, 35.1%) and MAC (n = 70, 34.7%) were the most common NTM species isolated, followed by M. chelonae-abscessus (n = 40, 19.8%) and M. kansasii (n = 21, 10.4%). The mean clinical follow-up period was 26.2 months. Forty-four patients (21.8%) had subsequent positive cultures of the same NTM species, while eight (4.0%) had bronchiectasis and developed NTM lung disease (NTM-LD). Neither patients without bronchiectasis nor those with M. fortuitum subsequently developed NTM lung disease. Among bronchiectatic patients with NTM other than M. fortuitum, age ≤65 years (p 0.006, OR 32.13), malignancy (p 0.048, OR 14.35), and initial radiographic score >2 (p 0.027, OR 20.06) were associated with subsequent NTM-LD. In all of the NTM patients, bronchiectasis (p <0.001, OR 5.46) and age ≤65 years (p 0.002, OR 3.29) were significantly associated with subsequent positive NTM culture. In patients with a single isolation of NTM from respiratory specimens, the presence of bronchiectasis and younger age indicates higher risk of subsequent culture-positivity and NTM-LD. Single isolation of M. fortuitum is of little clinical significance. Other patients with NTM, younger age, and more severe radiographic pulmonary lesion also warrant further attention.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical mycobacterial infections; bronchiectasis; nontuberculous mycobacterium; respiratory infections; single sputum isolate

Mesh:

Year:  2014        PMID: 25658545     DOI: 10.1016/j.cmi.2014.08.025

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.

Authors:  Víctor Vinuesa; Rafael Borrás; María Luisa Briones; María Ángeles Clari; Vicenta Cresencio; Estela Giménez; Carmen Muñoz; Rosa Oltra; Emilio Servera; Talia Scheelje; Carlos Tornero; David Navarro
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

2.  Prevalence of non-tuberculous mycobacteria in HIV-infected patients admitted to hospital with pneumonia.

Authors:  N C Lapinel; S E Jolley; J Ali; D A Welsh
Journal:  Int J Tuberc Lung Dis       Date:  2019-04-01       Impact factor: 2.373

3.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

4.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

5.  Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria.

Authors:  H Kotilainen; V Valtonen; P Tukiainen; T Poussa; J Eskola; A Järvinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-09       Impact factor: 3.267

6.  The trend and the disease prediction of vascular endothelial growth factor and placenta growth factor in nontuberculous mycobacterial lung disease.

Authors:  Chou-Han Lin; Chin-Chung Shu; Chia-Lin Hsu; Shih-Lung Cheng; Jann-Yuan Wang; Chong-Jen Yu; Li-Na Lee
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

7.  Predictors of developing Mycobacterium kansasii pulmonary disease within 1 year among patients with single isolation in multiple sputum samples: A retrospective, longitudinal, multicentre study.

Authors:  Hung-Ling Huang; Meng-Hsuan Cheng; Po-Liang Lu; Chia-Jung Liu; Inn-Wen Chong; Jann-Yuan Wang
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

8.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

9.  Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients: A Prospective Observational Study.

Authors:  Meng-Rui Lee; Chia-Jung Tsai; Wei-Jie Wang; Tzu-Yi Chuang; Chih-Mann Yang; Lih-Yu Chang; Ching-Kai Lin; Jann-Yuan Wang; Chin-Chong Shu; Li-Na Lee; Chong-Jen Yu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

10.  Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK.

Authors:  Eleanor L Axson; Navdeep Bual; Chloe I Bloom; Jennifer K Quint
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.